Last reviewed · How we verify
NCT03785067: TRIDENT COG
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study
Phase 3 trial testing telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg in Cognitive Decline in 1 participant. Terminated before completion.
3 February 2021
Quick facts
| Lead sponsor | The George Institute |
|---|---|
| Phase | Phase 3 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | screening |
| Enrollment | 1 |
| Start date | 27 February 2020 |
| Primary completion | 3 February 2021 |
| Estimated completion | 3 February 2021 |
| Sites | 4 locations across Netherlands, Australia |
Drugs / interventions tested
- telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg — full drug profile →
- Placebo oral capsule
Conditions studied
- Cognitive Decline — all drugs for Cognitive Decline →
- Intracerebral Hemorrhage — all drugs for Intracerebral Hemorrhage →
- Dementia, Vascular — all drugs for Dementia, Vascular →
- Cerebral Small Vessel Diseases — all drugs for Cerebral Small Vessel Diseases →
Sponsor
The George Institute
Who can join
18 and older, any sex, with Cognitive Decline or Intracerebral Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Sub-Study of an investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial (TRIDENT) to determine the effect of more intensive long-term blood pressure control, provided by a fixed low-dose combination blood pressure lowering pill ("Triple Pill") strategy on top of standard of care, for slowing memory decline as measured by Cambridge Neuropsychological Test Automated Battery (CANTAB), in patients with a history of acute stroke due to intracerebral haemorrhage (ICH).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03785067
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cognitive Decline
Currently open trials in the same condition.
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT07394504 — Effects of Turning Based Dual Task Training on Balance and Mild Cognitive Impairment in Diabetic Peripheral Neuropathy · NA · recruiting
- NCT07127965 — Exercise Adherence and Cognitive Decline: Phase 2 · NA · recruiting
- NCT07151365 — Plant-based Diets and Healthy Aging · recruiting
- NCT07399418 — TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics. · recruiting
Other The George Institute trials
Trials by the same sponsor.
- NCT07231315 — INTERACT4 Expansion - Validation Study · not yet recruiting
- NCT04157231 — Essential Acute Stroke Care in Low Resource Settings: a Pilot studY · NA · not yet recruiting
- NCT06935760 — Optimised Treatment for Hypertension Trial · NA · not yet recruiting
- NCT06409364 — FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage · Phase 2 · recruiting
- NCT06058585 — The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03785067 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The George Institute
- Last refreshed: 1 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03785067.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing